-
Biocon Biologics biosimilars for osteoporosis, cancer-related bone disease gets FDA nod
21 Sep 2025 15:25 GMT
New Delhi: Bengaluru-based Biocon fully integrated subsidiary Biocon Biologics announced that the … innovative brand is a monoclonal antibody engineered to block RANKL (Receptor … (~Rs 19,000 crore).
Alongside Biocon, Denosumab biosimilars is also marketed …
-
India-based Biocon Limited Establishes Cranbury, New Jersey, Production Operations
20 Sep 2025 04:18 GMT
… through its wholly owned subsidiary Biocon Generics Inc., has established … to affordable therapies worldwide.”
Biocon Limited develops and manufactures biopharmaceuticals … areas include biosimilar insulins, monoclonal antibodies for cancer and immunology, …
-
FDA Approves Biocon Biologics' Denosumab Biosimilars: Bosaya and Aukelso
19 Sep 2025 01:28 GMT
… The approvals, granted to Biocon Biologics, will provide more … CEO and managing director of Biocon Biologics, stated that the … is a human monoclonal antibody that works by targeting … , denosumab biosimilars. News release. Biocon Biologics. September 17, 2025. …
-
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
30 Jul 2025 17:00 GMT
… By Route of Antibody Type: Monoclonal Antibodies (mAbs), Bispecific Antibodies, Antibody Drug Conjugates, and … CO., LTD., AJINOMOTO CO., INC., Biocon, Eurofins Scientific, among others. Biologics …
-
Biocon Biologics expands biosimilar insulin portfolio with USFDA nod of Kirsty
16 Jul 2025 09:13 GMT
… company and subsidiary of Biocon Ltd., has received … approval of KIRSTY expands Biocon Biologics’ biosimilar insulin portfolio … .8M patients annually, Biocon Biologics has a comprehensive … insulins and monoclonal antibodies spanning multiple therapy areas.
-
Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US
16 Jul 2025 07:59 GMT
… company and subsidiary of Biocon announced that US … approval of Kirsty expands Biocon Biologics’ biosimilar insulin portfolio … CEO & managing director, Biocon Biologics, said: “The FDA … insulins and monoclonal antibodies spanning multiple therapy areas.
-
Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drug
16 Jul 2025 05:59 GMT
… .
This FDA approval significantly expands Biocon Biologics’ biosimilar insulin portfolio in … , and rapid-acting insulins.
Globally, Biocon Biologics serves over 5.8 … , including insulins and monoclonal antibodies.
On Tuesday, Biocon shares closed 3% higher …
-
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
15 Jul 2025 19:25 GMT
… assets, including insulins and monoclonal antibodies spanning multiple therapy areas. * … Biosimilars Newco Limited, a Biocon Biologics Company.
Biocon Biologics & Logo … 47;index.html About Biocon Biologics Limited: Biocon Biologics Limited, a subsidiary …
-
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
11 Jul 2025 11:55 GMT
… Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’ … is a human monoclonal antibody that is designed to … and survival of osteoclasts.
Biocon Biologics’ chief executive officer … after the EC approved Biocon Biologics’ Yesintek, an …
-
Biocon’s Denosumab biosimilars gain EU marketing authorisation
04 Jul 2025 11:01 GMT
Biocon Biologics’ Denosumab biosimilars, Vevzuo and … recommendation issued in April 2025.
Biocon Biologics CEO and managing director … .”
Denosumab, a human-derived monoclonal antibody, specifically attaches to the protein …
About
© 1995-2025